Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.

Volume: 216, Issue: 4, Pages: 966 - 981
Published: Apr 1, 2019
Abstract
Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function EZH2 mutations are common in myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the evolution of acute myeloid leukemia (AML), where we observed stage-specific and diametrically opposite functions for Ezh2 at the early and late stages of disease. During disease maintenance, WT Ezh2 exerts an oncogenic function...
Paper Details
Title
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
Published Date
Apr 1, 2019
Volume
216
Issue
4
Pages
966 - 981
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.